MovDisordV3, PascalFrancis, Curation, bibRecord, 001749

Efficacy and tolerability of entacapone versus cabergoline in parkinsonian patients suffering from wearing-off

Identifieur interne : 001749 ( PascalFrancis/Curation ); précédent : 001748; suivant : 001750

Efficacy and tolerability of entacapone versus cabergoline in parkinsonian patients suffering from wearing-off

Auteurs : Günther Deuschl [Allemagne] ; Antanas Vaitkus [Lituanie] ; Gabriele-Cornelia Fox [Allemagne] ; Torsten Roscher [Allemagne] ; Dieter Schremmer [Allemagne] ; Ariel Gordin [Allemagne]

Source :

Movement disorders [ 0885-3185 ] ; 2007.

RBID : Pascal:07-0448788

Descripteurs français

Pascal (Inist)
- Système nerveux pathologie, Parkinson maladie, Entacapone, Etude comparative, Cabergoline, Homme, Essai clinique.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Cabergoline, Clinical trial, Comparative study, Entacapone, Human, Nervous system diseases, Parkinson disease.

Abstract

In this 12-wk, multi-center, randomized, open-label, rater-blinded study, efficacy and tolerability of Entacapone (ENT) or Cabergoline (CBG) in conjunction with levodopa were compared in 161 older Parkinson's disease patients with wearing-off. Patients received either ENT, 3 to 5 times daily, or CBG, titrated according to requirements to a maximum of 6 mg/d. A significant decrease of nearly 2 hours in the daily OFF-time (primary efficacy variable) was recorded in both treatment groups. The non-inferiority test failed despite a trend in favor of ENT. Reduction in OFF-time occurred faster in the ENT compared to the CBG treated patients. A decrease of ∼20% was detected in parts II and III of the UPDRS, with no differences between the groups. Forty-three percent of the patients in the ENT group reported dyskinesias at baseline, and 35% at the final visit. The corresponding figures in the CBG group were 46% and 43%. Quality of life, measured by PDQ-39, increased substantially with both ENT and CBG. The mean daily dosage at the final visit was 698 mg for ENT (plus 447 mg levodopa) and 3.45 mg for CBG (plus 475 mg levodopa). Adverse events (AE), leading to discontinuation, were reported in 8.5% of the ENT and 13.9% of the CBG treated patients. Nausea was the most common AE in each group, corresponding figures being 7.3% with ENT and 25.3% with CBG (P = 0.0024). A probable or possible causal relationship with ENT was reported in 41% and with CBG in 64% of the AE. Among these, only one serious AE (dehydration) was recorded with each treatment group. ENT and CBG reduced the patient's motor complications effectively and to a similar degree. The clinical benefit was more quickly apparent with ENT, which also showed a more favorable AE profile than CBG.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 22`
A06				`@2 11`
A08	`01`	`1`	`ENG`	`@1 Efficacy and tolerability of entacapone versus cabergoline in parkinsonian patients suffering from wearing-off`
A11	`01`	`1`		`@1 DEUSCHL (Günther)`
A11	`02`	`1`		`@1 VAITKUS (Antanas)`
A11	`03`	`1`		`@1 FOX (Gabriele-Cornelia)`
A11	`04`	`1`		`@1 ROSCHER (Torsten)`
A11	`05`	`1`		`@1 SCHREMMER (Dieter)`
A11	`06`	`1`		`@1 GORDIN (Ariel)`
A14	`01`			`@1 Department of Neurology, Christian-Albrechts-Universität @2 Kiel @3 DEU @Z 1 aut.`
A14	`02`			`@1 Department of Neurology, Kaunas Medical University @2 Kaunas @3 LTU @Z 2 aut.`
A14	`03`			`@1 Medical Department, Orion Pharma @2 Hamburg @3 DEU @Z 3 aut. @Z 4 aut. @Z 6 aut.`
A14	`04`			`@1 Department of Biometrics, GKM @2 München @3 DEU @Z 5 aut.`
A17	`01`	`1`		`@1 CAMP Study Group @3 GEO`
A20				`@1 1550-1555`
A21				`@1 2007`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000149744800050`
A44				`@0 0000 @1 © 2007 INIST-CNRS. All rights reserved.`
A45				`@0 21 ref.`
A47	`01`	`1`		`@0 07-0448788`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 In this 12-wk, multi-center, randomized, open-label, rater-blinded study, efficacy and tolerability of Entacapone (ENT) or Cabergoline (CBG) in conjunction with levodopa were compared in 161 older Parkinson's disease patients with wearing-off. Patients received either ENT, 3 to 5 times daily, or CBG, titrated according to requirements to a maximum of 6 mg/d. A significant decrease of nearly 2 hours in the daily OFF-time (primary efficacy variable) was recorded in both treatment groups. The non-inferiority test failed despite a trend in favor of ENT. Reduction in OFF-time occurred faster in the ENT compared to the CBG treated patients. A decrease of ∼20% was detected in parts II and III of the UPDRS, with no differences between the groups. Forty-three percent of the patients in the ENT group reported dyskinesias at baseline, and 35% at the final visit. The corresponding figures in the CBG group were 46% and 43%. Quality of life, measured by PDQ-39, increased substantially with both ENT and CBG. The mean daily dosage at the final visit was 698 mg for ENT (plus 447 mg levodopa) and 3.45 mg for CBG (plus 475 mg levodopa). Adverse events (AE), leading to discontinuation, were reported in 8.5% of the ENT and 13.9% of the CBG treated patients. Nausea was the most common AE in each group, corresponding figures being 7.3% with ENT and 25.3% with CBG (P = 0.0024). A probable or possible causal relationship with ENT was reported in 41% and with CBG in 64% of the AE. Among these, only one serious AE (dehydration) was recorded with each treatment group. ENT and CBG reduced the patient's motor complications effectively and to a similar degree. The clinical benefit was more quickly apparent with ENT, which also showed a more favorable AE profile than CBG.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17F`
C02	`03`	`X`		`@0 002B16B`
C03	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 01`
C03	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 01`
C03	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 01`
C03	`02`	`X`	`FRE`	`@0 Parkinson maladie @5 02`
C03	`02`	`X`	`ENG`	`@0 Parkinson disease @5 02`
C03	`02`	`X`	`SPA`	`@0 Parkinson enfermedad @5 02`
C03	`03`	`X`	`FRE`	`@0 Entacapone @2 NK @2 FR @5 09`
C03	`03`	`X`	`ENG`	`@0 Entacapone @2 NK @2 FR @5 09`
C03	`03`	`X`	`SPA`	`@0 Entacapona @2 NK @2 FR @5 09`
C03	`04`	`X`	`FRE`	`@0 Etude comparative @5 10`
C03	`04`	`X`	`ENG`	`@0 Comparative study @5 10`
C03	`04`	`X`	`SPA`	`@0 Estudio comparativo @5 10`
C03	`05`	`X`	`FRE`	`@0 Cabergoline @2 NK @2 FR @5 11`
C03	`05`	`X`	`ENG`	`@0 Cabergoline @2 NK @2 FR @5 11`
C03	`05`	`X`	`SPA`	`@0 Cabergolina @2 NK @2 FR @5 11`
C03	`06`	`X`	`FRE`	`@0 Homme @5 12`
C03	`06`	`X`	`ENG`	`@0 Human @5 12`
C03	`06`	`X`	`SPA`	`@0 Hombre @5 12`
C03	`07`	`X`	`FRE`	`@0 Essai clinique @5 13`
C03	`07`	`X`	`ENG`	`@0 Clinical trial @5 13`
C03	`07`	`X`	`SPA`	`@0 Ensayo clínico @5 13`
C07	`01`	`X`	`FRE`	`@0 Encéphale pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
N21				`@1 295`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001572

Links to Exploration step

Pascal:07-0448788

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Efficacy and tolerability of entacapone versus cabergoline in parkinsonian patients suffering from wearing-off</title>
<author><name sortKey="Deuschl, Gunther" sort="Deuschl, Gunther" uniqKey="Deuschl G" first="Günther" last="Deuschl">Günther Deuschl</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Christian-Albrechts-Universität</s1>
<s2>Kiel</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Vaitkus, Antanas" sort="Vaitkus, Antanas" uniqKey="Vaitkus A" first="Antanas" last="Vaitkus">Antanas Vaitkus</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, Kaunas Medical University</s1>
<s2>Kaunas</s2>
<s3>LTU</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Lituanie</country>
</affiliation>
</author>
<author><name sortKey="Fox, Gabriele Cornelia" sort="Fox, Gabriele Cornelia" uniqKey="Fox G" first="Gabriele-Cornelia" last="Fox">Gabriele-Cornelia Fox</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Medical Department, Orion Pharma</s1>
<s2>Hamburg</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Roscher, Torsten" sort="Roscher, Torsten" uniqKey="Roscher T" first="Torsten" last="Roscher">Torsten Roscher</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Medical Department, Orion Pharma</s1>
<s2>Hamburg</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Schremmer, Dieter" sort="Schremmer, Dieter" uniqKey="Schremmer D" first="Dieter" last="Schremmer">Dieter Schremmer</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Biometrics, GKM</s1>
<s2>München</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Gordin, Ariel" sort="Gordin, Ariel" uniqKey="Gordin A" first="Ariel" last="Gordin">Ariel Gordin</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Medical Department, Orion Pharma</s1>
<s2>Hamburg</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">07-0448788</idno>
<date when="2007">2007</date>
<idno type="stanalyst">PASCAL 07-0448788 INIST</idno>
<idno type="RBID">Pascal:07-0448788</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001572</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001749</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Efficacy and tolerability of entacapone versus cabergoline in parkinsonian patients suffering from wearing-off</title>
<author><name sortKey="Deuschl, Gunther" sort="Deuschl, Gunther" uniqKey="Deuschl G" first="Günther" last="Deuschl">Günther Deuschl</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Christian-Albrechts-Universität</s1>
<s2>Kiel</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Vaitkus, Antanas" sort="Vaitkus, Antanas" uniqKey="Vaitkus A" first="Antanas" last="Vaitkus">Antanas Vaitkus</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, Kaunas Medical University</s1>
<s2>Kaunas</s2>
<s3>LTU</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Lituanie</country>
</affiliation>
</author>
<author><name sortKey="Fox, Gabriele Cornelia" sort="Fox, Gabriele Cornelia" uniqKey="Fox G" first="Gabriele-Cornelia" last="Fox">Gabriele-Cornelia Fox</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Medical Department, Orion Pharma</s1>
<s2>Hamburg</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Roscher, Torsten" sort="Roscher, Torsten" uniqKey="Roscher T" first="Torsten" last="Roscher">Torsten Roscher</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Medical Department, Orion Pharma</s1>
<s2>Hamburg</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Schremmer, Dieter" sort="Schremmer, Dieter" uniqKey="Schremmer D" first="Dieter" last="Schremmer">Dieter Schremmer</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Biometrics, GKM</s1>
<s2>München</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Gordin, Ariel" sort="Gordin, Ariel" uniqKey="Gordin A" first="Ariel" last="Gordin">Ariel Gordin</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Medical Department, Orion Pharma</s1>
<s2>Hamburg</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cabergoline</term>
<term>Clinical trial</term>
<term>Comparative study</term>
<term>Entacapone</term>
<term>Human</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Parkinson maladie</term>
<term>Entacapone</term>
<term>Etude comparative</term>
<term>Cabergoline</term>
<term>Homme</term>
<term>Essai clinique</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">In this 12-wk, multi-center, randomized, open-label, rater-blinded study, efficacy and tolerability of Entacapone (ENT) or Cabergoline (CBG) in conjunction with levodopa were compared in 161 older Parkinson's disease patients with wearing-off. Patients received either ENT, 3 to 5 times daily, or CBG, titrated according to requirements to a maximum of 6 mg/d. A significant decrease of nearly 2 hours in the daily OFF-time (primary efficacy variable) was recorded in both treatment groups. The non-inferiority test failed despite a trend in favor of ENT. Reduction in OFF-time occurred faster in the ENT compared to the CBG treated patients. A decrease of ∼20% was detected in parts II and III of the UPDRS, with no differences between the groups. Forty-three percent of the patients in the ENT group reported dyskinesias at baseline, and 35% at the final visit. The corresponding figures in the CBG group were 46% and 43%. Quality of life, measured by PDQ-39, increased substantially with both ENT and CBG. The mean daily dosage at the final visit was 698 mg for ENT (plus 447 mg levodopa) and 3.45 mg for CBG (plus 475 mg levodopa). Adverse events (AE), leading to discontinuation, were reported in 8.5% of the ENT and 13.9% of the CBG treated patients. Nausea was the most common AE in each group, corresponding figures being 7.3% with ENT and 25.3% with CBG (P = 0.0024). A probable or possible causal relationship with ENT was reported in 41% and with CBG in 64% of the AE. Among these, only one serious AE (dehydration) was recorded with each treatment group. ENT and CBG reduced the patient's motor complications effectively and to a similar degree. The clinical benefit was more quickly apparent with ENT, which also showed a more favorable AE profile than CBG.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>22</s2>
</fA05>
<fA06><s2>11</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Efficacy and tolerability of entacapone versus cabergoline in parkinsonian patients suffering from wearing-off</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>DEUSCHL (Günther)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>VAITKUS (Antanas)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>FOX (Gabriele-Cornelia)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>ROSCHER (Torsten)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>SCHREMMER (Dieter)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>GORDIN (Ariel)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurology, Christian-Albrechts-Universität</s1>
<s2>Kiel</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Neurology, Kaunas Medical University</s1>
<s2>Kaunas</s2>
<s3>LTU</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Medical Department, Orion Pharma</s1>
<s2>Hamburg</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Biometrics, GKM</s1>
<s2>München</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA17 i1="01" i2="1"><s1>CAMP Study Group</s1>
<s3>GEO</s3>
</fA17>
<fA20><s1>1550-1555</s1>
</fA20>
<fA21><s1>2007</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000149744800050</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2007 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>21 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>07-0448788</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>In this 12-wk, multi-center, randomized, open-label, rater-blinded study, efficacy and tolerability of Entacapone (ENT) or Cabergoline (CBG) in conjunction with levodopa were compared in 161 older Parkinson's disease patients with wearing-off. Patients received either ENT, 3 to 5 times daily, or CBG, titrated according to requirements to a maximum of 6 mg/d. A significant decrease of nearly 2 hours in the daily OFF-time (primary efficacy variable) was recorded in both treatment groups. The non-inferiority test failed despite a trend in favor of ENT. Reduction in OFF-time occurred faster in the ENT compared to the CBG treated patients. A decrease of ∼20% was detected in parts II and III of the UPDRS, with no differences between the groups. Forty-three percent of the patients in the ENT group reported dyskinesias at baseline, and 35% at the final visit. The corresponding figures in the CBG group were 46% and 43%. Quality of life, measured by PDQ-39, increased substantially with both ENT and CBG. The mean daily dosage at the final visit was 698 mg for ENT (plus 447 mg levodopa) and 3.45 mg for CBG (plus 475 mg levodopa). Adverse events (AE), leading to discontinuation, were reported in 8.5% of the ENT and 13.9% of the CBG treated patients. Nausea was the most common AE in each group, corresponding figures being 7.3% with ENT and 25.3% with CBG (P = 0.0024). A probable or possible causal relationship with ENT was reported in 41% and with CBG in 64% of the AE. Among these, only one serious AE (dehydration) was recorded with each treatment group. ENT and CBG reduced the patient's motor complications effectively and to a similar degree. The clinical benefit was more quickly apparent with ENT, which also showed a more favorable AE profile than CBG.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17F</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B16B</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Entacapone</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Entacapone</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Entacapona</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Etude comparative</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Comparative study</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Estudio comparativo</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Cabergoline</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Cabergoline</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Cabergolina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Homme</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Human</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Hombre</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Essai clinique</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Clinical trial</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Ensayo clínico</s0>
<s5>13</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>295</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001749 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 001749 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:07-0448788
   |texte=   Efficacy and tolerability of entacapone versus cabergoline in parkinsonian patients suffering from wearing-off
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Efficacy and tolerability of entacapone versus cabergoline in parkinsonian patients suffering from wearing-off

Efficacy and tolerability of entacapone versus cabergoline in parkinsonian patients suffering from wearing-off

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri